INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
SEC FORM 4/Grant or awardVerified data

Hartley Dylan reported OKUR

Chief Scientific Officer · OnKure Therapeutics, Inc. · OnKure Therapeutics, Inc. — Employee Stock Option (right to buy)

Side
A
Value
—
Shares
137.6K
Price
—
Executed
Aug 7, 2026
Disclosed
Aug 11, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Aug 7 executedAug 11, 2026 disclosed

OKUR · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · OKUR

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    26
    SA
    Saccomano Nicholas ADirector, President and CEO
    OKUROnKure Therapeutics, Inc.
    Open-market sale
    		SELL$259
    87 sh
    		Sep 21, 2026Sep 23, 2026
    traded Sep 21, 2026
    		+2dSEC FORM 4

    Evidence

    26
    LA
    Leverone Jason A.Chief Financial Officer
    OKUROnKure Therapeutics, Inc.
    Open-market sale
    		SELL$898
    302 sh
    		Sep 21, 2026Sep 23, 2026
    traded Sep 21, 2026
    		+2dSEC FORM 4

    Evidence

    9
    AS
    Agresta SamuelChief Medical Officer
    OKUROnKure Therapeutics, Inc.
    Grant or award
    		A—
    131.4K sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    9
    JM
    Jansen Valerie MalyvanhDirector
    OKUROnKure Therapeutics, Inc.
    Grant or award
    		A—
    22.4K sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    9
    AS
    Agresta SamuelChief Medical Officer
    OKUROnKure Therapeutics, Inc.
    Disposition to issuer
    		D—
    131.4K sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    9
    HD
    Hartley DylanChief Scientific Officer
    OKUROnKure Therapeutics, Inc.
    Grant or award
    		A—
    50.0K sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    9
    AS
    Agresta SamuelChief Medical Officer
    OKUROnKure Therapeutics, Inc.
    Grant or award
    		A—
    50.0K sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    9
    HD
    Hartley DylanChief Scientific Officer
    OKUROnKure Therapeutics, Inc.
    Disposition to issuer
    		D—
    137.6K sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    9
    PJ
    Phillips Andrew JohnDirector
    OKUROnKure Therapeutics, Inc.
    Grant or award
    		A—
    22.4K sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    9
    AS
    Agresta SamuelChief Medical Officer
    OKUROnKure Therapeutics, Inc.
    Disposition to issuer
    		D—
    18.6K sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    9
    AS
    Agresta SamuelChief Medical Officer
    OKUROnKure Therapeutics, Inc.
    Grant or award
    		A—
    18.6K sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    9
    PJ
    Phillips Andrew JohnDirector
    OKUROnKure Therapeutics, Inc.
    Grant or award
    		A—
    7,650 sh
    		Jun 4, 2026Jun 8, 2026
    traded Jun 4, 2026
    		+4dSEC FORM 4

    Evidence

    9
    JM
    Jansen Valerie MalyvanhDirector
    OKUROnKure Therapeutics, Inc.
    Grant or award
    		A—
    7,650 sh
    		Jun 4, 2026Jun 8, 2026
    traded Jun 4, 2026
    		+4dSEC FORM 4

    Evidence

    9
    HD
    Hartley DylanChief Scientific Officer
    OKUROnKure Therapeutics, Inc.
    Grant or award
    		A—
    110.0K sh
    		Apr 1, 2026Apr 3, 2026
    traded Apr 1, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002037442-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Aug 7, 2026
    Published
    Aug 11, 2026
    Ingested by INSIDER
    Nov 5, 02:23 UTC
    Last re-read
    Nov 5, 02:23 UTC

    Extracted facts

    Filer
    Hartley Dylan
    Role
    Chief Scientific Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    OnKure Therapeutics, Inc. — Employee Stock Option (right to buy)
    Ticker
    OKUR
    Shares
    137.6K
    Execution date (reported)
    Aug 7, 2026
    Owned after transaction
    137.6K shares
    Days from execution to publication
    4

    What this establishes

    Hartley Dylan filed this Form 4 reporting a grant or award of OKUR on Aug 7, 2026. It became public on Aug 11, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Scientific Officer
    Hartley Dylancik:0002037442
    Issuer
    OnKure Therapeutics, Inc.cik:0001637715

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.